247 related articles for article (PubMed ID: 9552061)
1. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
Laczika K; Novak M; Hilgarth B; Mitterbauer M; Mitterbauer G; Scheidel-Petrovic A; Scholten C; Thalhammer-Scherrer R; Brugger S; Keil F; Schwarzinger I; Haas OA; Lechner K; Jaeger U
J Clin Oncol; 1998 Apr; 16(4):1519-25. PubMed ID: 9552061
[TBL] [Abstract][Full Text] [Related]
2. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
3. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
[TBL] [Abstract][Full Text] [Related]
4. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
5. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
Marcucci G; Caligiuri MA; Döhner H; Archer KJ; Schlenk RF; Döhner K; Maghraby EA; Bloomfield CD
Leukemia; 2001 Jul; 15(7):1072-80. PubMed ID: 11455976
[TBL] [Abstract][Full Text] [Related]
6. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B
Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
8. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
[TBL] [Abstract][Full Text] [Related]
9. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
[TBL] [Abstract][Full Text] [Related]
10. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
[TBL] [Abstract][Full Text] [Related]
11. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
Krauter J; Hoellge W; Wattjes MP; Nagel S; Heidenreich O; Bunjes D; Ganser A; Heil G
Genes Chromosomes Cancer; 2001 Apr; 30(4):342-8. PubMed ID: 11241787
[TBL] [Abstract][Full Text] [Related]
12. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.
Buonamici S; Ottaviani E; Testoni N; Montefusco V; Visani G; Bonifazi F; Amabile M; Terragna C; Ruggeri D; Piccaluga PP; Isidori A; Malagola M; Baccarani M; Tura S; Martinelli G
Blood; 2002 Jan; 99(2):443-9. PubMed ID: 11781223
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
[TBL] [Abstract][Full Text] [Related]
14. Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.
Martinelli G; Rondoni M; Buonamici S; Ottaviani E; Piccaluga PP; Malagola M; Baccarani M
Haematologica; 2004 Apr; 89(4):495-7. PubMed ID: 15075086
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
[TBL] [Abstract][Full Text] [Related]
16. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
[TBL] [Abstract][Full Text] [Related]
17. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission.
Tobal K; Johnson PR; Saunders MJ; Harrison CJ; Liu Yin JA
Br J Haematol; 1995 Sep; 91(1):104-8. PubMed ID: 7577615
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
[TBL] [Abstract][Full Text] [Related]
19. Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13).
Fujiki A; Imamura T; Furutani A; Hatano W; Asai D; Hirashima Y; Miyachi M; Tamura S; Tsuchiya K; Iehara T; Ishida H; Yoshihara T; Hosoi H
J Pediatr Hematol Oncol; 2012 Jul; 34(5):402-5. PubMed ID: 22278196
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
Sugimoto T; Das H; Imoto S; Murayama T; Gomyo H; Chakraborty S; Taniguchi R; Isobe T; Nakagawa T; Nishimura R; Koizumi T
Am J Hematol; 2000 Jun; 64(2):101-6. PubMed ID: 10814988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
